Skip to main content
. 2019 Nov;96(5):527–541. doi: 10.1124/mol.118.115113

TABLE 1.

X-ray structures of class A and B GPCRs in which the allosteric ligands are bound to transmembrane lipid-facing binding sites, which can be accessed only through lipid pathways

GPCR Class Receptor Allosteric Ligand Name PDB ID Bilayer Depth (Å)a Major Species at pH 7.4 Solvent-Accessible Surface Area (SASA)b
Ligand Lipophilicity Unbound Ligand
Bound Ligand
C log P log D7.4 Total (Å2) Polar (%) Nonpolar (%) MESA (%) BSA (%)
A GPR40 TAK-875c 4PHU 16.1 1.30 1.23 Negative 656.5 49.8 50.2 31 69
GPR40 MK-8666c 5TZR 16.4 3.75 1.62 Negative 913.4 16.8 83.2 34 66
GPR40 AP8d 5TZY 30.5 5.23 4.05 Zwitterionic 923.9 15.6 84.4 34 66
P2Y1 BPTUe 4XNV 22.7 7.50 5.53 Neutral 739.8 34.8 65.2 40 60
PAR2 AZ3451e 5NDZ 18.0 7.96 6.37 Neutral 773.1 18.1 81.9 43 57
B CRF1R CP-376395e 4K5Y 23.6 7.61 5.7 Positive 658.1 49.4 50.6 39 61
GCGR MK-0893e 5EE7 31.6 4.88 3.42 Negative 971.6 9.9 90.1 44 56
GLP1R PF-06372222f 5VEW 34.7 4.61 −0.53 Negative 908.3 13.3 86.7 30 70
GLP1R NNC0640f 5VEX 31.0 4.08 1.28 Positive 976.2 41.5 58.5 45 55

CRF1R, corticotropin-releasing factor 1 receptor; GLP1R, glucagon-like peptide 1 receptor; GPR40, free fatty acid receptor 1; PAR2, protease-activated receptor 2.

a

Binding site location (bilayer depth) within the membrane, measured as the distance between center of mass (COM) of the ligand and that of the phosphorus atoms in the upper leaflet, measured along the bilayer normal.

b

Calculated using NACCESS (Hubbard and Thornton, 1993) with a probe of radius 1.4 Å; C log P: 1-octanol/water partition coefficients calculated using Bio-Loom for Windows version 1.5 (2006); log D7.4: partition coefficient at pH 7.4 that was calculated using ACD/Percepta (Advanced Chemistry Development, Inc., Toronto, ON, 2015). For bilayer depth calculation, the membrane-embedded crystal structures were obtained from the OPM database (Lomize et al., 2012). The average bilayer thickness was 36.92 Å for all the studied receptors.

c

Partial agonist.

d

Full allosteric agonists, AgoPAMs.

e

Antagonist.

f

Negative allosteric modulator.